Team outlines potential target for aggressive breast cancer vaccine

Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed. The condition affects 12% of 1.4 million new breast cancer cases annually, leaving its patients with limited treatment options because TNBC doesn't express three protein markers targeted by conventional therapies. The team's findings, published in Clinical Cancer Research, demonstrate that the "HAGE" molecule may have immunogenic qualities beneficial for a TNBC vaccine. Story | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.